Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FEMY vs TPST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FEMY Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–2 Matrix Metrics)

FEMY Overall Winner 6-Pillar Tally: FEMY 4 – 1 TPST (1 Tie) Matrix Metrics: FEMY 4 – 2 TPST

As of Nov 16, 2026, Femasys Inc. (FEMY) is the stronger overall head-to-head candidate over Tempest Therapeutics, Inc. (TPST) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas TPST carries 39.3/100 (SELL) at $0.34 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. TPST 39.3/100 SELL) and 4.01β · 72% Vol risk profile, whereas TPST leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile TPST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FEMY vs TPST
FEMY NASDAQ Head-to-Head Winner
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92
TPST NASDAQ
Tempest Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.34
-10.5% 1D
Market Cap $7.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.75β · 89% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 25.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.3%), weak momentum, RSI 25
RSI-14: 24.7 · SMA20: $0.46 · SMA50: $0.67

6-Pillar Scorecard Institutional Category Breakdown (FEMY 4 – 1 TPST)

Columns: Metric · FEMY · TPST
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x N/M
2. Growth & Scale TPST
Revenue Growth (YoY) -18.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M N/A
Market Cap $11.9M $7.6M
3. Profitability & Quality FEMY
Gross Margin 60.9% N/A
Operating Margin -763.9% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -425.0% -1797.6%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$19M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -$658,045 Net Debt (0.65x D/E) $6.8M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FEMY
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FEMY (4) vs TPST (2)
Institutional Metric FEMY TPST Criterion Row Edge
Market Capitalization
Scale
$11.9M $7.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-18.9% +0.0% Higher Growth TPST
Operating Margin (TTM)
Profitability
-763.9% 0.0% Higher Margin TPST
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-425.0% -1797.6% Higher ROE FEMY
52-Week Range Position
Momentum
17% ($0–$6) 0% ($0–$10) Stronger Trend FEMY
Beta / 30D Volatility
Risk Regime
4.01β · 72% Vol 0.75β · 89% Vol Lower Realized Risk FEMY
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 39.3 / 100 (SELL) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M (-$658,045 Net Debt (0.65x D/E)) N/A ($6.8M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FEMY +22.82 pp
FEMY: -22.42% · TPST: -45.24%
3M Horizon FEMY +26.24 pp
FEMY: -41.82% · TPST: -68.06%
6M Horizon FEMY +334.03 pp
FEMY: +252.81% · TPST: -81.22%
1Y Horizon FEMY +150.92 pp
FEMY: +54.78% · TPST: -96.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FEMY Revenue TPST Revenue FEMY Op. Margin TPST Op. Margin Margin Leader
FY2016 N/A $0M N/A -12406.1% TPST
FY2017 N/A $0M N/A -28585.1% TPST
FY2020 $0M N/A -668.0% N/A FEMY
FY2021 $0M N/A -706.7% N/A FEMY
FY2022 $0M N/A -961.7% N/A FEMY
FY2023 $0M N/A -1353.4% N/A FEMY
FY2024 $0M N/A -1091.8% N/A FEMY
FY2025 $0M N/A -767.0% N/A FEMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TPST BREAKDOWN
40d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TPST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TPST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FEMY vs TPST Key Questions & Quantitative Answers

As of Nov 16, 2026, Femasys Inc. (FEMY) is the stronger overall head-to-head candidate over Tempest Therapeutics, Inc. (TPST) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas TPST carries 39.3/100 (SELL) at $0.34 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. TPST 39.3/100 SELL) and 4.01β · 72% Vol risk profile, whereas TPST leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile TPST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TPST leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with TPST at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), FEMY cumulative revenue shifted N/A while TPST shifted N/A. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TPST.

FEMY screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas TPST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus TPST (-1797.6% ROE) capital efficiency.

In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, TPST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.75β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.